ASX ANNOUNCEMENT
4 April 2022

Biome Australia launches new acne probiotic to retail partners

- Biome has successfully launched its newest condition-specific probiotic *Biome Acne™ Probiotic* for sale to its network of over 2500 community pharmacies and independent health practitioners
- This follows the recent publication of an independent clinical trial confirming the efficacy of Biome Acne's probiotic strains in treating acne lesions
- Biome aims to use this new product innovation to further develop its relationships with and expand its network of healthcare practitioners, and improve patients' quality of life

---

Microbiome health company **Biome Australia Limited** (ASX: BIO) ('Biome' or 'the company') is pleased to announce it has successfully launched its newest condition-specific live biotherapeutic product, *Biome Acne™ Probiotic*, following the completion of an independent clinical study in February (Ref announcement 9 & 14 February 2022).

The result of the study demonstrated that the *Biome Acne™* probiotic strains reduced the number of acne lesions by 31.11% in just four weeks, which was statistically significant ($p < 0.05$) when compared to placebo (10% reduction), with a 38.89% reduction after 8 weeks (compared to a 18.89% reduction in the placebo group, $p < 0.05$).

Biome Acne™ Probiotic has now been distributed for sale to Biome's network of retail partners which include over 2500 community pharmacies and independent health practitioners.

First shipments have been sent to fill initial pre-launch orders from Biome's wholesale customers which includes its pharmacy distributors Symbion and API, and its independent health practitioner distributors Oborne Health, Rener Health, Vital.ly and Ariya.

The release of this new product under the Activated Probiotics® brand, and the first of Biome's products to target the symptoms of acne, provides significant commercial opportunities for the company to develop its relationships with and expand its network of healthcare practitioners to improve the quality of life for the many people who experience acne.

Biome Australia Managing Director and Founder Blair Norfolk said: "The understanding of what acne is has changed over the last few years: it's a chronic inflammatory disease and new technology should aim to address this inflammation. Biome Acne™ Probiotic targets skin inflammation and acne via the immune system in the gut".

Biome Australia showcased the Activated Probiotics range, including *Biome Acne,* at the Australian Pharmacy Professional Conference (APP) on the Gold Coast from 24-27 March 2022. This event is the largest national gathering of pharmacy professionals, Biome Australia's customers. Some images of the APP conference and the new product, *Biome Acne*, are shown below.



Certified B Corporation

Biome Australia Limited
Head Office: 16 Dover Street, Cremorne VIC 3121 AUSTRALIA

(03) 9017 5800 support@activated.co www.biomeaustralia.com

ABN: 51 627 364 014





Certified B Corporation

Biome Australia Limited
Head Office: 16 Dover Street, Cremorne VIC 3121 AUSTRALIA

(03) 9017 5800 support@activated.co www.biomeaustralia.com

ABN: 51 627 364 014

–ENDS–

Approved for release by the Biome Australia board of directors.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range, Activated Nutrients® and a sports performance and recovery range, Activated X Performance®, which is made exclusively for professional athletes.

For more information visit: www.biomeaustralia.com

Investor Relations
WE Communications
Hannah Howlett
+61 450 648 064
hhowlett@we-worldwide.com

Media enquiries
media@activated.co

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance. The historic financial information for the September 2021 financial quarter and revenue figures for October and November 2021 have not been audited or reviewed by Biome's auditors. Such information should not be taken as a guide for future performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.